2 completed, 2 recruiting, 1 not yet recruiting. 3 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow sudapyridine: new trials by email Literature Review of sudapyridine trials Research Report on sudapyridine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Drug-Drug Interaction and Food Effect of Sudapyridine(WX-081) With Itraconazole and Rifampin in Healthy Chinese Adults Sudapyridine, Itraconazole, Rifampin - Rifampicin-Resistant Pulmonary Tuberculosis Patients | Phase 1 | Not yet recruiting | Shanghai Jiatan Pharmatech Co., Ltd | 16 | 2025-05-12 | 2025-02-12 |
| Pharmacokinetic Study of Sudapyridine（WX-081）in Healthy Chinese Subjects [U-14C] WX-081 - TB | Phase 1 | Recruiting | Shanghai Jiatan Pharmatech Co., Ltd | 10 | 2024-09-04 | 2024-11-22 |
| A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients Sudapyridine, Bedaquiline - Rifampin-Resistant Pulmonary Tuberculosis, Tuberculosis, Multidrug-Resistant (MDR-TB) | Phase 3 | Recruiting | Shanghai Jiatan Pharmatech Co., Ltd | 450 | 2022-09-02 | 2025-06-29 |
| Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081 WX-081, Bedaquiline, Standard treatment - Pulmonary Tuberculosis | Phase 2 | Completed | Shanghai Jiatan Pharmatech Co., Ltd | 99 | 2020-10-16 | 2023-09-11 |
| Sudapyridine (WX-081) in Healthy Volunteers Sudapyridine 30mg, Sudapyridine 100mg SAD, Sudapyridine 200mg SAD - Healthy | Phase 1 | Completed | Shanghai Jiatan Pharmatech Co., Ltd | 82 | 2019-02-13 | 2023-11-07 |
Tuberculosis (2) · Tuberculosis, Pulmonary (2) · Tuberculosis, Multidrug-Resistant (1)
Shanghai Jiatan Pharmatech Co., Ltd (5)
China (4)
Naihui Chu, Ph.D (1) · Song AiYun, MD (1) · Yun Liu (1)